End points
metabolic acidosis, hyperkalemia, peritonitis
METABOLIC ACIDOSIS, IRON DEFICIENCY, PERITONITIS
The primary efficacy endpoints were the changes of iron biomarker levels from baseline to week 24 including hepcidin, sTFR, serum iron (SI), sFt, TSAT, total iron binding capacity (TIBC), and the proportion of patients with absolute iron deficiency (defined as TSAT < 20% and sFt < 100 ng/mL) and functional iron deficiency (defined as TSAT < 20% and sFt ≥ 100 ng/mL). Secondary efficacy endpoints were as follows: the hemoglobin levels at weeks 8 and 24, the proportion of patients who achieved the treatment target (defined as a mean hemoglobin level greater than or equal to 100 g/L but less than 120 g/L), the mean changes from baseline in lipid metabolism levels, and the incidence of hyperkalemia, metabolic acidosis and peritonitis.